NCT07384377 2026-02-03
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
Shanghai JMT-Bio Inc.
Ningbo Newbay Technology Development Co., Ltd
Shanghai JMT-Bio Inc.
Shanghai Runshi Pharmaceutical Technology Co., Ltd